174 related articles for article (PubMed ID: 11513186)
1. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C.
van Rossum TG; Vulto AG; Hop WC; Schalm SW
Am J Gastroenterol; 2001 Aug; 96(8):2432-7. PubMed ID: 11513186
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial.
Orlent H; Hansen BE; Willems M; Brouwer JT; Huber R; Kullak-Ublick GA; Gerken G; Zeuzem S; Nevens F; Tielemans WC; Zondervan PE; Lagging M; Westin J; Schalm SW
J Hepatol; 2006 Oct; 45(4):539-46. PubMed ID: 16905220
[TBL] [Abstract][Full Text] [Related]
3. [Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study].
Mao YM; Zeng MD; Chen Y; Chen CW; Fu QC; Cai X; Wu SM; Chen YG; Sun Y; Li J; Sui YH; Zhao W; Lu LG; Cao AP; Chen HZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):847-51. PubMed ID: 19958646
[TBL] [Abstract][Full Text] [Related]
4. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
[TBL] [Abstract][Full Text] [Related]
5. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial.
van Rossum TG; Vulto AG; Hop WC; Brouwer JT; Niesters HG; Schalm SW
J Gastroenterol Hepatol; 1999 Nov; 14(11):1093-9. PubMed ID: 10574137
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of diphenyl-dimethyl-dicarboxylate plus garlic oil in patients with chronic hepatitis.
Lee MH; Kim YM; Kim SG
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):778-86. PubMed ID: 22943930
[TBL] [Abstract][Full Text] [Related]
8. Does Silybum marianum play a role in the treatment of chronic hepatitis C?
Torres M; Rodríguez-Serrano F; Rosario DJ; Rodríguez-Perez F; Toro DH
P R Health Sci J; 2004 Jun; 23(2 Suppl):69-74. PubMed ID: 16929590
[TBL] [Abstract][Full Text] [Related]
9. Randomized double blind placebo-controlled trial of a Chinese herbal therapy (CH100) in chronic hepatitis C.
Mollison L; Totten L; Flexman J; Beaman M; Batey R
J Gastroenterol Hepatol; 2006 Jul; 21(7):1184-8. PubMed ID: 16824073
[TBL] [Abstract][Full Text] [Related]
10. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
11. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.
Huber R; Lüdtke R; Klassen M; Müller-Buscher G; Wolff-Vorbeck G; Scheer R
Eur J Med Res; 2001 Sep; 6(9):399-405. PubMed ID: 11669085
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C.
Pardo M; Castillo I; Oliva H; Fernández-Flores A; Bárcena R; de Peuter MA; Carreño V
Hepatology; 1997 Nov; 26(5):1318-21. PubMed ID: 9362378
[TBL] [Abstract][Full Text] [Related]
14. A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-alpha.
O'Brien CB; Moonka DK; Henzel BS; Caufield M; DeBruin MF
Am J Gastroenterol; 2001 Aug; 96(8):2473-9. PubMed ID: 11513193
[TBL] [Abstract][Full Text] [Related]
15. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C.
Sakai T; Shiraki K; Inoue H; Okano H; Deguchi M; Sugimoto K; Ohmori S; Murata K; Nakano T
Int J Mol Med; 2002 Aug; 10(2):201-4. PubMed ID: 12119559
[TBL] [Abstract][Full Text] [Related]
17. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years.
Persico M; Perrotta S; Persico E; Terracciano L; Folgori A; Ruggeri L; Nicosia A; Vecchione R; Mura VL; Masarone M; Torella R
J Viral Hepat; 2006 May; 13(5):290-6. PubMed ID: 16637858
[TBL] [Abstract][Full Text] [Related]
19. Daily interferon therapy for chronic hepatitis C: a report of a community practice experience.
Srinivas D; Mani H; Crumpler C; Van Thiel DH
Hepatogastroenterology; 2002; 49(46):1053-7. PubMed ID: 12143200
[TBL] [Abstract][Full Text] [Related]
20. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.
Rino Y; Tarao K; Morinaga S; Ohkawa S; Miyakawa K; Hirokawa S; Masaki T; Tarao N; Yukawa N; Saeki H; Takanashi Y; Imada T
Anticancer Res; 2006; 26(3B):2221-6. PubMed ID: 16821591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
